statistiche ricercatore

COSCIA, MARTA

Distribuzione geografica

Continente	#
NA - Nord America	5.780
AS - Asia	3.808
EU - Europa	1.451
SA - Sud America	507
AF - Africa	95
OC - Oceania	10
Totale	11.651

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	5.599
SG - Singapore	1.820
CN - Cina	652
HK - Hong Kong	619
BR - Brasile	428
IT - Italia	325
VN - Vietnam	319
GB - Regno Unito	270
RU - Federazione Russa	233
FR - Francia	232
BD - Bangladesh	134
FI - Finlandia	110
DE - Germania	96
MX - Messico	88
IN - India	71
CA - Canada	69
NG - Nigeria	38
IQ - Iraq	32
TR - Turchia	30
ZA - Sudafrica	28
NL - Olanda	27
SE - Svezia	26
AR - Argentina	24
JP - Giappone	24
AT - Austria	22
ES - Italia	20
PL - Polonia	20
SA - Arabia Saudita	16
LT - Lituania	14
CO - Colombia	13
IE - Irlanda	13
PK - Pakistan	13
ID - Indonesia	11
UA - Ucraina	11
UZ - Uzbekistan	11
VE - Venezuela	11
AU - Australia	9
EC - Ecuador	9
MD - Moldavia	9
MY - Malesia	8
CH - Svizzera	7
CL - Cile	7
KE - Kenya	7
NP - Nepal	7
AE - Emirati Arabi Uniti	6
JO - Giordania	6
EE - Estonia	5
EG - Egitto	5
HN - Honduras	5
JM - Giamaica	5
PH - Filippine	5
MA - Marocco	4
TN - Tunisia	4
BE - Belgio	3
BO - Bolivia	3
CR - Costa Rica	3
CZ - Repubblica Ceca	3
IR - Iran	3
PE - Perù	3
PS - Palestinian Territory	3
PY - Paraguay	3
TT - Trinidad e Tobago	3
BG - Bulgaria	2
DZ - Algeria	2
ET - Etiopia	2
GT - Guatemala	2
GY - Guiana	2
IL - Israele	2
KG - Kirghizistan	2
LB - Libano	2
NI - Nicaragua	2
OM - Oman	2
SR - Suriname	2
UY - Uruguay	2
AM - Armenia	1
BB - Barbados	1
BH - Bahrain	1
BS - Bahamas	1
CI - Costa d'Avorio	1
CY - Cipro	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
HU - Ungheria	1
KH - Cambogia	1
KR - Corea	1
KZ - Kazakistan	1
LK - Sri Lanka	1
LY - Libia	1
NZ - Nuova Zelanda	1
PT - Portogallo	1
QA - Qatar	1
SN - Senegal	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
TG - Togo	1
TL - Timor Orientale	1
TZ - Tanzania	1
Totale	11.651

Salva come PNG Salva come JPEG

Città	#
San Jose	1.622
Singapore	1.009
Hong Kong	609
Ashburn	533
Chicago	478
Council Bluffs	433
Dallas	380
The Dalles	253
Boardman	236
Beijing	204
Lauterbourg	196
London	190
Ho Chi Minh City	118
Los Angeles	113
New York	101
Helsinki	94
Santa Clara	93
Hanoi	80
Orem	75
Mexico City	67
São Paulo	48
Brooklyn	44
San Francisco	41
Abuja	38
Denver	37
Atlanta	34
Munich	28
Houston	27
Nuremberg	27
Assago	26
Chennai	26
Manchester	26
Milan	25
Tokyo	23
Frankfurt am Main	22
Montreal	22
Phoenix	22
Rome	22
Johannesburg	21
Stockholm	20
Da Nang	19
Boston	18
Warsaw	18
Guangzhou	16
Poplar	16
Salt Lake City	16
Toronto	16
Haiphong	15
Shanghai	15
Ankara	14
Turku	14
Baghdad	13
Buffalo	13
Dublin	13
Shenzhen	13
Amsterdam	11
Belo Horizonte	11
Hangzhou	11
Rio de Janeiro	11
Seattle	11
Tashkent	11
Tianjin	11
Elk Grove Village	9
Flanders	9
Porto Alegre	9
Vergiate	9
Calgary	8
Chandler	8
Düsseldorf	8
Moscow	8
Secaucus	8
Vienna	8
Charlotte	7
Miami	7
Nairobi	7
New Delhi	7
Oklahoma City	7
Riyadh	7
Zhengzhou	7
Amman	6
Cavaria con Premezzo	6
Contagem	6
Fairfield	6
Fort Worth	6
Fortaleza	6
Honolulu	6
Indianapolis	6
Piracicaba	6
Romola	6
Salvador	6
São José dos Campos	6
Brasília	5
Campinas	5
Campo Grande	5
Caracas	5
Detroit	5
Erbil	5
Guidonia Montecelio	5
Jacksonville	5
Jeddah	5
Totale	8.019

Salva come PNG Salva come JPEG

Nome	#
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs	599
AISF position paper on HCV in immunocompromised patients	155
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY	85
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia	81
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma	78
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	77
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: a retrospective real‐life multicenter Italian cohort	76
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway	75
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia	71
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience	71
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells	71
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	70
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS	68
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	68
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide	68
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials	67
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs	67
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment	66
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib	65
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study	65
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	65
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS	65
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS	64
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape	64
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation	63
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification	63
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment	63
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia	63
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy	63
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide	62
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia	62
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	61
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives	61
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	61
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	60
HLA-G is a component of the CLL escape repertoire to generate immune suppression: impact of HLA-G 14 bp (rs66554220) polymorphism	60
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia	60
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)	59
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice	59
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	59
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges	59
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene	59
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino	58
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA	58
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study	57
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status	56
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells	56
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL)	56
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells	55
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy	55
Effective anti-tumor immunomodulatory properties of zoledronic acid	54
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	53
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia	53
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study	53
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	53
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	52
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study	52
Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification	52
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA	52
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status	52
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation	52
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients	51
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL	51
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22	51
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia	51
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside	51
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study	51
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications	51
Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells	51
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET	51
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells	51
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients	51
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome	50
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF)	50
Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study	50
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia	50
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells	50
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia	50
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence	50
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	50
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL	50
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	49
FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY	49
NEW PROSPECTS FOR INDUCTION OF ANTI-LYMPHOMA IMMUNITY USING DNA VACCINES EXPRESSING CHEMOKINE-PARTICLES	49
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	49
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy	49
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)	49
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up	49
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis	49
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs	49
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia	49
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial	49
Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study	49
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial	48
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response	48
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL)	48
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia	48
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells	48
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	48
LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA	48
Totale	6.362

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	57.781
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	57.781

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	4	0	0	0	0	0	0	0	0	0	0	0	4
2021/2022	7	0	0	2	0	0	0	0	1	1	1	1	1
2022/2023	23	2	1	3	1	3	3	0	3	5	0	0	2
2023/2024	27	4	5	5	5	6	0	0	1	0	0	0	1
2024/2025	3.434	239	34	868	158	181	118	136	111	283	200	222	884
2025/2026	8.370	411	465	436	846	458	399	2.377	348	788	536	945	361
Totale													11.894